<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532830</url>
  </required_header>
  <id_info>
    <org_study_id>M-US-01</org_study_id>
    <nct_id>NCT01532830</nct_id>
  </id_info>
  <brief_title>Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine</brief_title>
  <official_title>Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElectroCore LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElectroCore LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to assess feasibility and clarify the design of future
      study(ies) to support marketing approval of the GammaCore™ device for the treatment and/or
      prevention of migraine symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">July 25, 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Number of Participants With Adverse Effects</measure>
    <time_frame>End of Study - 7 weeks</time_frame>
    <description>The primary outcome measure for this study was the assessment of adverse events as unanticipated or anticipated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Headache Pain From Baseline to 120 Minutes</measure>
    <time_frame>120 minutes</time_frame>
    <description>Headache was measured on a 4 point scale where 0 = no pain, 1 = mild, 2 = moderate, 3 = severe pain at baseline (start of attack), 5, 15, 30, 45, 60, 90 and 120 minutes.
Data presented shows the average change from baseline to 120 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Photophobia (Visual) From Baseline to 120 Minutes</measure>
    <time_frame>Base line and 120 minutes</time_frame>
    <description>Presence of photophobia (yes or no) was captured at baseline and 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Phonophobia (Auditory) From Baseline to 120 Minutes</measure>
    <time_frame>120 minutes</time_frame>
    <description>Presence of phonophobia (yes or no) was captured at baseline 5, 15, 30, 45, 60, 90, 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Nausea From Baseline to 120 Minutes</measure>
    <time_frame>Baseline 120 minutes</time_frame>
    <description>Nausea was captured in the diary and measured on a 4 point scale, where 0 = no nausea, 1 = mild, 2 = moderate and 3 = severe nausea, at baseline and 120 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Functional Disability</measure>
    <time_frame>Baseline and 120 minutes</time_frame>
    <description>Functional disability was captured in the diary and measured on a 4 point scale, where 0 = no disability, able to function normally and where 3 = performance of daily activities severely impaired, measured at baseline and 120 minutes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>n-VNS active therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>n-VNS</intervention_name>
    <arm_group_label>Active</arm_group_label>
    <other_name>gammaCore</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is between the ages of 18 and 55 years.

          -  Has been previously diagnosed as suffering from migraine, in accordance with the
             ICHD-2 Classification criteria (2nd), with or without aura.

          -  Experiences at least 2 migraines per month, but less than 15 headache days per month
             (over the last 3 months).

          -  Has age of onset of migraine less than 50 years old.

          -  Is able to give written Informed Consent

        Exclusion Criteria:

          -  Has a history of aneurysm, intracranial hemorrhage, brain tumors or significant head
             trauma.

          -  Has a lesion (including lymphadenopathy) at the GammaCore™ treatment site.

          -  Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid
             artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF),
             coronary artery disease or recent myocardial infarction.

          -  Has a history or baseline ECG that identifies the presence of a clinically significant
             unstable cardiac arrhythmia, second degree heart block type II, history of ventricular
             tachycardia or ventricular fibrillation, or known cardiac syndromes that may be
             associated with increased risk of sudden death in otherwise healthy people.

          -  Has had a previous bilateral or right cervical vagotomy.

          -  Has a clinically significant irregular heart rate or rhythm.

          -  Has uncontrolled high blood pressure.

          -  Is currently implanted with an electrical and/or neurostimulator device, including but
             not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal
             stimulator, bone growth stimulator, or cochlear implant.

          -  Has a history of carotid endarterectomy or vascular neck surgery on the right side.

          -  Has been implanted with metal cervical spine hardware or has a metallic implant near
             the GammaCore™ stimulation site.

          -  Has a recent or repeated history of syncope.

          -  Has a recent or repeated history of seizure.

          -  Has a history or suspicion of narcotic abuse.

          -  Takes medication for acute headaches more than 10 days per month.

          -  Is pregnant, nursing, thinking of becoming pregnant in the next 3 months, or of
             childbearing years and is unwilling to use an accepted form of birth control.

          -  Is participating in any other therapeutic clinical investigation or has participated
             in a clinical trial in the preceding 30 days.

          -  Belongs to a vulnerable population or has any condition such that his or her ability
             to provide informed consent, comply with follow-up requirements, or provide
             self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).

          -  Is a relative of or an employee of the investigator or the clinical study site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF Headache Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Headache Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Headache Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014 Oct;34(12):986-93. doi: 10.1177/0333102414524494. Epub 2014 Mar 7.</citation>
    <PMID>24607501</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>March 7, 2018</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2018</results_first_posted>
  <disposition_first_submitted>February 23, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 5, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 6, 2018</disposition_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vagus nerve stimulation</keyword>
  <keyword>vagal nerve stimulation</keyword>
  <keyword>nVNS</keyword>
  <keyword>VNS</keyword>
  <keyword>migraine</keyword>
  <keyword>non invasive</keyword>
  <keyword>gammacore</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>gammaCore Device</title>
          <description>non-invasive vagus nerve stimulator gammaCore: treatment with gammaCore vagus nerve stimulator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized population</population>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>n-VNS active therapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" lower_limit="19" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety - Number of Participants With Adverse Effects</title>
        <description>The primary outcome measure for this study was the assessment of adverse events as unanticipated or anticipated.</description>
        <time_frame>End of Study - 7 weeks</time_frame>
        <population>Randomized population</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Number of Participants With Adverse Effects</title>
          <description>The primary outcome measure for this study was the assessment of adverse events as unanticipated or anticipated.</description>
          <population>Randomized population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unanticipated Adverse Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticipated Adverse Effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Headache Pain From Baseline to 120 Minutes</title>
        <description>Headache was measured on a 4 point scale where 0 = no pain, 1 = mild, 2 = moderate, 3 = severe pain at baseline (start of attack), 5, 15, 30, 45, 60, 90 and 120 minutes.
Data presented shows the average change from baseline to 120 minutes</description>
        <time_frame>120 minutes</time_frame>
        <population>Randomized population. 2 subjects were excluded from the analysis due to protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Headache Pain From Baseline to 120 Minutes</title>
          <description>Headache was measured on a 4 point scale where 0 = no pain, 1 = mild, 2 = moderate, 3 = severe pain at baseline (start of attack), 5, 15, 30, 45, 60, 90 and 120 minutes.
Data presented shows the average change from baseline to 120 minutes</description>
          <population>Randomized population. 2 subjects were excluded from the analysis due to protocol deviations</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean baseline pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean 120 minutes pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Photophobia (Visual) From Baseline to 120 Minutes</title>
        <description>Presence of photophobia (yes or no) was captured at baseline and 120 minutes.</description>
        <time_frame>Base line and 120 minutes</time_frame>
        <population>Randomized population. Data was missing for 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Photophobia (Visual) From Baseline to 120 Minutes</title>
          <description>Presence of photophobia (yes or no) was captured at baseline and 120 minutes.</description>
          <population>Randomized population. Data was missing for 3 patients</population>
          <units>migraines with photophobia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Migraine attacks with photophobia at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine attacks with photophobia at 120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Phonophobia (Auditory) From Baseline to 120 Minutes</title>
        <description>Presence of phonophobia (yes or no) was captured at baseline 5, 15, 30, 45, 60, 90, 120 minutes.</description>
        <time_frame>120 minutes</time_frame>
        <population>Randomized population. Data was missing for 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Phonophobia (Auditory) From Baseline to 120 Minutes</title>
          <description>Presence of phonophobia (yes or no) was captured at baseline 5, 15, 30, 45, 60, 90, 120 minutes.</description>
          <population>Randomized population. Data was missing for 3 patients</population>
          <units>migraines with phonophobia</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Migraine attacks with phonophobia at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine attacks with phonophobia at 120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Nausea From Baseline to 120 Minutes</title>
        <description>Nausea was captured in the diary and measured on a 4 point scale, where 0 = no nausea, 1 = mild, 2 = moderate and 3 = severe nausea, at baseline and 120 minutes.</description>
        <time_frame>Baseline 120 minutes</time_frame>
        <population>Randomized population. Data was missing for 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Nausea From Baseline to 120 Minutes</title>
          <description>Nausea was captured in the diary and measured on a 4 point scale, where 0 = no nausea, 1 = mild, 2 = moderate and 3 = severe nausea, at baseline and 120 minutes.</description>
          <population>Randomized population. Data was missing for 3 patients</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea severity at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea severity at 120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Functional Disability</title>
        <description>Functional disability was captured in the diary and measured on a 4 point scale, where 0 = no disability, able to function normally and where 3 = performance of daily activities severely impaired, measured at baseline and 120 minutes.</description>
        <time_frame>Baseline and 120 minutes</time_frame>
        <population>Randomized population. Data was missing for 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>n-VNS active therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Functional Disability</title>
          <description>Functional disability was captured in the diary and measured on a 4 point scale, where 0 = no disability, able to function normally and where 3 = performance of daily activities severely impaired, measured at baseline and 120 minutes.</description>
          <population>Randomized population. Data was missing for 3 patients</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean disability score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean disability score at 120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>n-VNS active therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tinnitus left ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiff Neck</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Discomfort to the neck into the upper right shoulder with tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neck swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Right shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Right shoulder spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neck twitched a little during use of the device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lip drooping during use of the device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Facial drooping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Raspiness of voice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck redness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs</name_or_title>
      <organization>electroCore LLC</organization>
      <phone>+1 973 355 6683</phone>
      <email>clinical@electrocore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

